NCT06005116 is a NA clinical trial of [68Ga]-NOTA-SGC8 in Bladder Cancer, sponsored by RenJi Hospital.

Who is sponsoring NCT06005116?

NCT06005116 is sponsored by RenJi Hospital.

What drugs are being tested in NCT06005116?

Interventions in NCT06005116: [68Ga]-NOTA-SGC8.

What condition does NCT06005116 study?

NCT06005116 studies Bladder Cancer.

Is NCT06005116 still recruiting?

NCT06005116 is currently status unknown. Last updated 22 August 2023.

Last reviewed 2023-08-22 · How we verify

NCT06005116

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[68Ga] NOTA-SGC8 in the Staging of Bladder Cancer

Status unknown NA Last updated 22 August 2023

What this trial tests

NA trial testing [68Ga]-NOTA-SGC8 in Bladder Cancer in 64 participants. Status unknown.

Timeline

15 September 2023

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	RenJi Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	64
Start date	15 September 2023
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

[68Ga]-NOTA-SGC8

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 80, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the imaging and diagnostic ability of \[68Ga\]-NOTA-SGC8 PET/MR in bladder cancer patients with different stages. The main questions it aims to answer are: * Tumor specific lighting ability of \[68Ga\]-NOTA-SGC8 in bladder cancer patients with different stages. * The safety of \[68Ga\]-NOTA-SGC8. Participants will be irrigated with \[68Ga\]-NOTA-SGC8 into the bladder for tumor imaging under PET/MR. The imaging performance of \[68Ga\]-NOTA-SGC8 on different stages of bladder tumors will be systematically evaluated by combining with pathological sections of patients. Urine accumulation and radioactivity distribution of \[68Ga\]-NOTA-SGC8 will be measured. The adverse events will be recorded.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.
Liu M, Wang Y, Zhang Y, Hu D, et al · · 2025 · cited 62× · PMID 40059188 · DOI 10.1038/s41392-024-02112-8
Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview.
Mottard K, Cokaiko J, Rogister B, Neirinckx V. · · 2025 · cited 6× · PMID 39468753 · DOI 10.1093/oncolo/oyae290
Cytotoxicity of <sup>212</sup>Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.
Lindland K, Juzeniene A. · · 2025 · cited 1× · PMID 40885785 · DOI 10.1186/s41181-025-00382-3
The emerging role of aptamers in targeted cancer immunotherapy.
Zhu S, Xu R, Xu H, Wang Y, et al · · 2026 · PMID 41659919 · DOI 10.1016/j.omton.2025.201110

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06005116 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 22 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06005116.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing